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Solid organ transplant recipients (SOTRs) have a
2.4-fold increased risk for melanoma.1 Renal trans-
plant recipients have an incidence of melanoma up
to 8 times greater than the comparison immunocom-
petent population.2
Posttransplant melanomas diagnosed at a later
stage (Breslow depth 1.51-3.00 mm3 and T3/T4 stage
tumors4) have worse survival rates than non-SOTRs
with melanoma. Immunosuppressive therapy for
kidney transplantation or autoimmune disease at
the time of melanoma diagnosis is associated with a
greater risk of death frommelanoma, suggesting that
melanomas in the setting of immunosuppression are
more likely to metastasize.5
The following case report documents the aggres-
sive behavior of a melanoma in a kidney transplant
patient. Because later stage melanomas in SOTRs
have a high risk for metastasis, practitioners will
benefit from understanding how immunosuppres-
sion influences the choice of treatment among the
growing number of systemic medications approved
by the US Food and Drug Administration (FDA) for
the treatment of metastatic melanoma.CASE REPORT
A 43-year-old woman with a history of non-
melanoma skin cancers noted a changing skin lesion
over her right deltoid. The lesion was initially
unsuccessfully treated with cryotherapy. Her medi-
cal history was significant for kidney and pancreas
transplantation from a deceased donor at the age of
36 secondary to childhood diabetes and pregnancy-
associated renal complications. Immunosuppressivethe Department of Dermatologya and Division of Hematol-
y-Oncology,b Department of Medicine, Hospital of the
iversity of Pennsylvania.
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uzar.shin@uphs.upenn.edu.medications included tacrolimus, 2 mg twice daily,
mycophenolate mofetil, 500 mg twice daily, and
prednisone, 5 mg daily.
An excisional biopsy found a nonulcerated ma-
lignant melanoma, nodular type, with a Breslow
thickness of 10 mm (Clark level V), and 37 mitoses
per mm2 (American Joint Committee on Cancer
tumor stage T4a). Tumor-infiltrating lymphocytes,
radial growth phase, microsatellitosis, lymphovascu-
lar invasion, and perineural invasion were absent.
She underwent wide local excision and sentinel
lymph node biopsy. There was a microscopic focus
(\0.1 cm) of residual melanoma in the subcutaneous
fat adjacent to scar, less than 0.1 cm from the deep
margin. Malignant melanomawas present in the right
axillary sentinel lymph node. Positron emission
tomography/computed tomography scan showed
no evidence of metastatic disease. Right axillary
lymph node dissection found malignant melanoma
in 1 of 37 lymph nodes. The largest tumor deposit
was 2.5 mm without extracapsular invasion. Her
American Joint Committee on Cancer stage was stage
IIIB (T4a, N2a, M0).
The medical oncology department recommended
reduction of immunosuppression and activeJAAD Case Reports 2015;1:S26-8.
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Table I. FDA-approved systemic treatments for melanoma
Therapeutic options Year of approval Mechanism Indications
Cytotoxic chemotherapeutic agents
Dacarbazine7-9 1975 Cell-cycle nonspecific DNA
alkylation
Unresectable or metastatic melanoma
Immune therapy
High-dose interleukin-2 1998 Enhance host immune function Unresectable or metastatic melanoma
IFN-a9-11 1996
2011
(pegylated IFN)
Enhance host immune function,
possible direct tumor effects
Adjuvant therapy after surgery for
melanoma metastatic to lymph nodes
MAPK pathway Inhibitors
Vemurafenib 2011 BRAF inhibitor Unresectable or metastatic melanoma
Dabrafenib 2013 BRAF inhibitor Unresectable or metastatic melanoma
Trametinib 2013 MEK inhibitor Unresectable or metastatic melanoma
Immune checkpoint inhibitors
Ipilimumab12 2011 CTLA-4 blockade Unresectable or metastatic melanoma
Pembrolizumab 2014 PD-1 receptor blockade Unresectable or metastatic melanoma,
disease progression after ipilimumab
and BRAF inhibitor (if V600E1)
CTLA, Cytotoxic T-lymphocyteeassociated protein 4; PD-1, programmed death-1.
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mofetil was discontinued, but tacrolimus and predni-
sone were continued.
Thirteen months after diagnosis, pneumonia
developed, and a computed tomography scan of
the chest showed multiple pulmonary and hepatic
metastases. Imaging of the abdomen and pelvis did
not show any additional metastatic foci.
Brain metastases subsequently developed, and she
completed stereotactic radiosurgery to the left pons
and right centrum semiovale (1600 cGy to each site).
Weeks later, multiple new supratentorial metastases
developed, and the patient underwent palliative
whole brain radiation (3000 cGy total dose).
Fourteen months after the initial diagnosis, the
patient presented with multiple palpable right axil-
lary nodes. Fine-needle aspiration showed mela-
noma. BRAF testing had previously found wild-type
status, and chemotherapy with temozolomide was
initiated.
Interval imaging performed at 20 months after the
initial diagnosis found innumerable pulmonary me-
tastases and new liver and bone metastases. The
patient died of metastatic melanoma 21 months after
the initial diagnosis.
DISCUSSION
Evidence indicates that SOTRs have worse out-
comes compared with immunocompetent patients
for posttransplant melanomas diagnosed at Breslow
depths $ 1.5 mm.3,4 Even in the absence of
transplant-associated immunosuppression, the tumor
characteristics for our patient portended an unfavor-
able prognosis. Reduction of immunosuppression,which was done in our patient, is recommended in
the setting of posttransplant melanoma.6 However, it
is unknown how this affects survival.6
Since 2011, the number of FDA-approved sys-
temic therapies for melanoma has proliferated from
3 to 8 drugs (Table I).13 None are specifically
contraindicated in SOTRs according to the FDA-
approved package inserts. All, with the exception
of dacarbazine, carry a theoretic risk of graft
rejection. Many additional medications are in clin-
ical trials.14
Our patient potentially qualified for FDA-
approved systemic therapy at 2 points: (1) for
adjuvant therapy after wide local excision of the
primary tumor and axillary lymph node dissection of
metastatic disease and (2) 13 months after her initial
treatment when distant organ metastases were
detected.
Because SOTRs with intermediate and deep
primary melanomas have increased risk for poor
outcomes,3,4 effective adjuvant treatment would be
useful. Interferon alfa (IFN-a) is the only FDA-
approved adjuvant systemic therapy. The landmark
clinical trials for IFN-a15,16 did not include immuno-
suppressed patients, and the use of IFN-a in this
population causes concern for organ rejection.
Indeed, the few cases reported in the literature
treated metastatic melanoma in kidney transplant
recipients with IFN-a either in conjunction with
withdrawal of immunosuppression or removal of
the transplanted kidney.7,10,11 Because of a marginal
survival benefit for IFN-a and the possibility to enroll
patients in clinical trials with more effective medica-
tions, its use has declined. Immunosuppression
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trials, and we did not treat our patient with IFN-a.
SOTRs with metastatic melanoma have especially
poor prognosis, as illustrated by the rapid decline of
our patient from widespread metastasis. Our patient
was treated with temozolomide, an oral prodrug of
dacarbazine. There are scarce outcome data
regarding the use of dacarbazine or temozolomide
specifically in SOTRs.7,8
Immunotherapy with interleukin-2 has not been
studied in SOTRs. However, the risk of organ
rejection and potentially life-threatening capillary
leak syndrome and the small percentage of patients
who achieve durable remission may limit its use in
SOTRs.
Our patient did not qualify for treatment with
mitogen-activated protein kinase (MAPK) pathway
inhibitors because of wild-type BRAF status. The 3
FDA-approved MAPK pathway inhibitors could
potentially be used in SOTRs, although data
regarding their safety and efficacy are lacking.
We are aware of a single publication describing the
use of an immune checkpoint inhibitor in SOTRs.12
The authors report 2 cases of metastatic melanoma in
kidney transplant recipients who were treated with
ipilimumab. Both patients had partial responses,
remained on low-dose prednisone monotherapy,
and maintained stable kidney function. The use of
ipilimumab and pembrolizumab in SOTRs remains
uncertain, as immunosuppressed patients were
excluded from the clinical development of both
therapies. The theoretic concern for their use in
SOTRs is the risk for organ rejection caused by the
immunostimulatory effects of these 2 agents.
This case report illustrates a current practice gap
regarding the safety and efficacy of systemic thera-
pies to treat metastatic melanoma in SOTRs and the
need for additional study in this field. Because
immunosuppression excludes SOTRs from most
clinical trials for adjuvant and systemic chemo-
therapy, initial experience with these drugs in
SOTRS may occur outside of the clinical trials setting.
Currently, we evaluate each SOTR patient individu-
ally, with treatment decisions based on careful
consideration of the risks and potential benefits of
systemic therapy options in the context of their
immune suppression.REFERENCES
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